Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 4/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15812535 | 1.00 | GAA (0.44) | GAAMAPTBRD4CREBBPCA1 | |
| SCHEMBL3139036 | 0.81 | GAA (0.47) | GAAMAPTBRD4CREBBPCA1 | |
| SCHEMBL4215459 | 0.77 | GAA (0.51) | GAAMAPTBRD4CREBBPCA1 | |
| SCHEMBL28510430 | 0.76 | GAA (0.46) | GAAMAPTBRD4CREBBPCA1 | |
| SCHEMBL7134900 | 0.72 | GAA (0.46) | GAAMAPTBRD4CREBBPMTNR1A | |
| SCHEMBL12837999 | 0.70 | CREBBP (0.55) | GAAMAPTBRD4CREBBPEP300 | |
| SCHEMBL1736809 | 0.70 | CREBBP (0.55) | GAAMAPTBRD4CREBBPEP300 | |
| SCHEMBL33268 | 0.70 | CREBBP (0.55) | GAAMAPTBRD4CREBBPEP300 | |
| SCHEMBL29572486 | 0.70 | CREBBP (0.55) | GAAMAPTBRD4CREBBPEP300 | |
| SCHEMBL1868013 | 0.70 | CREBBP (0.55) | GAAMAPTBRD4CREBBPEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | GAA 3762/4885MAPT 301/4885BRD4 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.